Therapeutic approaches to the control of coronary atherosclerosis

  • W. G. Nayler
Conference paper

Summary

Atherosclerosis is a multifactorial disease which culminates in the ruptured plaque seen at autopsy. Hypercholesterolaemia, subintimal accumulation of lipid, monocyte adhesion followed by penetration across the endothelium, the conversion of monocytes to macrophages and smooth muscle cell proliferation and migration are some of the events involved in the early stages of lesion formation. Late events include the formation of excess ground substance and collagen, and the formation of the fibrotic cap. Young lesions tend to be more fragile than “old” calcified lesions, and it is these young lesions which rupture, haemorrhage and provide anchor points for platelets.

Therapeutic interventions aimed at controlling lesion formation include those which reduce risk factors, including hypertension as well as those which interfere with the cascade of events involved in lesion formation. Agents which lower plasma cholesterol provide one approach. Another approach is to use calcium antagonists which not only lower blood pressure, but also directly interfere with some of the metabolic events involved in lesion formation.

Key words

Calcium antagonists Nifedipine Nisoldipine Cholesterol Atherogenesis oxyradicals 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Daly MJ, Elz JS, Nayler WG (1987) Contracture and the calcium paradox in the rat heart. Circ Res 61: 560–569PubMedGoogle Scholar
  2. 2.
    Fleckenstein A, Frey M, Thimm F, Fleckenstein-Grun G (1990) Excessive mural calcium overload a predominant causal factor in the development of stenosing coronary plaques in humans. Cardiovasc Drugs Ther 4: 1005–1014PubMedCrossRefGoogle Scholar
  3. 3.
    Fuster V, Stein B, Ambrose JA, Badimon I, Badimon JJ, Chesbro JH (1990) Atherosclerotic plaque rupture and thrombis: evolving concepts. Circulation 82 (Suppl II): 11–47–11–59Google Scholar
  4. 4.
    Gottlieb SO, Brinker JA, Mellitis ED, Aschuff SC, Baughman KL. Traill TA, Weiss JL, Reitz BA, Weisfeldt M, Gerstenblith G (1989) Effect of nifedipine on the development of coronary bypass graft stenosis in high-risk patients: a randomized double-blind, placebo- controlled trial. Circulation 80 (Suppl 2) 11–228 (abstract)Google Scholar
  5. 5.
    Henry PD, Bentley KI (1981) Suppression of atherogenesis in cholesterol-fed rabbits treated with nifedipine. J Clin Invest 68: 1366–1369PubMedCrossRefGoogle Scholar
  6. 6.
    Kramsch DM, Aspen AJ, Rozier LJ (1981) Atherosclerosis: prevention by agents not affecting abnormal levels of blood lipids.Science 213: 1511–1512PubMedGoogle Scholar
  7. 7.
    Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW (1990) Retardation of angiographic progression of coronary artery disease by nifedipine. Lancet 335: 1109–1113PubMedCrossRefGoogle Scholar
  8. 8.
    Loaldi A, Polese A, Montorsi P, De Cesare N, Fabbiocchi F, Ravagnani P, Guazzi M (1989) Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary artery narrowing in angina pectoris. Am J Cardiol 64: 433–439PubMedCrossRefGoogle Scholar
  9. 9.
    Nayler WG (1991) Molecular mechanisms involved in the anti-atherogenic effect of the calcium antagonists. In: Nayler WG, The Second Generation of Calcium Antagonists, Springer Verlag, Berlin, pp 139–151Google Scholar
  10. 10.
    Nayler WG, Pangiotopoulos S (1986) Calcium antagonism. In: Kelly DT(ed) Proceedings of II Asian Pacific Adalat Symposium, ADIS Press, New Zealand, pp 3–11Google Scholar
  11. 11.
    Neuser D, Rosen B (1990) Calcium antagonists and the proliferation of vascular smooth muscle cells. Satellite Symposium of 13th ISH meeting Montreal “Antiatherosclerotic Potential of Calcium Antagonists” pp 9–10Google Scholar
  12. 12.
    Nilsson I, Sjolund M, Palmberg L, Von Euler AM, Jonzon B, Thyborg I (1985) The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation. Atherosclerosis 58: 109–112PubMedCrossRefGoogle Scholar
  13. 13.
    Orekov AN, Tertov VU, Khashimov KA, Kudryashou SA, Smirnov VN (1986) Anti- atherosclerotic effects of verapamil in primary culture of human aortic intimal cells. J Hypertens 4 (Suppl 6): S 153–155Google Scholar
  14. 14.
    Ranganthan S, Jackson RL (1984) Effect of calcium channel blocking drugs on lysosomal function in human skin fibroblasts. Biochem Pharmacol 33: 2377–2382CrossRefGoogle Scholar
  15. 15.
    Ross R (1981) Atherosclerosis: a problem of the biology of arterial wall cells and their interactions with blood components. Arteriosclerosis 1: 293–311PubMedCrossRefGoogle Scholar
  16. 16.
    Ross R (1986) The pathogenesis of atherosclerosis - an update. New England J Med 314: 488–500CrossRefGoogle Scholar
  17. 17.
    Ross R, Glomset JA (1976) The pathogenesis of atherosclerosis. New England J Med 295: 369–377CrossRefGoogle Scholar
  18. 18.
    Schwartz CJ, Kelley J, Nerem RM, Sprague EA (1989) Pathophysiology of the atherogenic process. Am J Cardiol 64: 236–305CrossRefGoogle Scholar
  19. 19.
    Stein O, Stein Y (1987) Effect of verapamil on cholesteryl ester hydrolysis and re-esteiifica- tion in macrophages. Atherosclerosis 7: 578–584Google Scholar
  20. 20.
    Stein O, Halpenis G, Stein Y (1987) Long term effects of verapamil on aortic smooth muscle cells cultured in the presence of hypercholesterolaemic serum. Atherosclerosis 7: 585–592Google Scholar
  21. 21.
    Tonks BD (1967) The estimation of cholesterol in serum: a classification and critical review of methods. Clin Biochem 1: 12–29CrossRefGoogle Scholar
  22. 22.
    Ware JA, Johnson PC, Smith M, Salzman EW (1986) Inhibition of human platelet aggrega-tion and cytoplasmic calcium response by calcium antagonists. Circ Res 59: 39–42PubMedGoogle Scholar
  23. 23.
    Waters D, Lesperance J, Francetich M, Causey D, Theroux P, Chiang Y-K, Hudon G, Lemarbre L, Reitman M, Joyal M, Gosselin G, Dyrda I, Macer J, Havel RJ (1990) A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 82: 1940–1953PubMedCrossRefGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt 1994

Authors and Affiliations

  • W. G. Nayler
    • 1
  1. 1.Department of MedicineThe University of Melbourne, Austin HospitalHeidelbergAustralia

Personalised recommendations